-
May 21, 2013
Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders
-
February 13, 2013
Theravance Inc.'s (THRX) fourth quarter 2012 loss of 33 cents per share was narrower than the Zacks Consensus loss ...
-
February 11, 2013
Warner Chilcott (WCRX) recently revealed its financial guidance for 2013. The company expects to earn $3.20-$3.30 ...
-
February 06, 2013
ArQule, Inc. (ARQL) and partner Daiichi Sankyo recently announced that former has enrolled the first patient for the ...
-
January 31, 2013
Pluristem Therapeutics, Inc. (PSTI) recently announced that it has taken possession of its new state-of-the-art ...
-
January 28, 2013
Theravance, Inc. (THRX) recently announced that it has completed its public offering of $287.5 million convertible ...
-
January 17, 2013
Theravance, Inc. (THRX) announced recently that it intends to offer $250 million convertible subordinated notes, due ...
-
January 15, 2013
GlaxoSmithKline (GSK) recently announced the submission of a marketing application to the US Food and Drug ...
-
January 10, 2013
GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced the submission of a marketing application to ...
-
January 07, 2013
Israel-based Pluristem Therapeutics, Inc. (PSTI) recently announced the initiation of the final validation steps for ...
-
December 31, 2012
We recently reiterated a Neutral recommendation on United Therapeutics (UTHR). While the company reported strong ...
-
December 28, 2012
Vanguard has long been the king of low cost products. Its structure, which has the ETFs be a separate share class of ...
-
December 24, 2012
GlaxoSmithKline (GSK) recently announced that it has received US Food and Drug Administration (FDA) approval for its ...
-
December 21, 2012
GlaxoSmithKline (GSK) and partner Amicus Therapeutics (FOLD) recently presented disappointing top-line six-month ...
-
December 20, 2012
GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced that they have submitted a marketing ...
-
December 18, 2012
GlaxoSmithKline (GSK) recently announced that its inhalational anthrax candidate, raxibacumab, has received US Food ...
-
December 18, 2012
Switzerland-based Actelion (ALIOF) recently announced that the US Food and Drug Administration (FDA) accepted its ...
-
December 13, 2012
This morning has been rocky for the market. The Nasdaq is down 0.4%; the S&P 500 has declined 0.3%; and the Dow has ...
-
December 13, 2012
The Nasdaq has decreased 0.4%, the S&P 500 has fallen 0.3% and the Dow is down 0.2% on a bad morning for the market. ...
-
December 05, 2012
Theravance, Inc. (THRX) recently announced the commencement of a phase II study (n~375) regarding its pipeline ...
